6550--Phadia Reagents & Supplies (5-YR BPA: 4/1/2026 to 3/31/2031)

Key Dates

Due Date

Posted Date

Agency & Value

Agency

241-NETWORK CONTRACT OFFICE 01 (36C241)

Contract Value

Not provided

Codes & Classification

Solicitation Number

36C24126Q0190

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Classification Code

6550

Additional Details

Set Aside

None

Place of Performance

—

SourceSAM

Documents2

This procurement notice announces the award of a five-year Blanket Purchase Agreement (BPA) for Phadia reagents and supplies, covering the period from April 1, 2026, through March 31, 2031. The agreement is managed by the 241-Network Contract Office 01 (36C241), a federal office under the Department of Veterans Affairs. The primary objective of this BPA is to ensure a consistent and reliable supply of in-vitro diagnostic substances, specifically Phadia-branded reagents and related consumables, which are essential for laboratory testing and diagnostic services within the VA healthcare system. The scope of this procurement encompasses the ongoing provision of high-quality reagents and supplies necessary for in-vitro diagnostic applications. These materials are critical for supporting the VA’s mission to deliver accurate and timely laboratory results, thereby enhancing patient care for veterans. The BPA structure allows for streamlined ordering and fulfillment processes over the five-year term, ensuring operational continuity and efficiency. This award is classified under NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing), indicating that the products supplied are specialized substances used in laboratory diagnostics. The Product Service Code (PSC) is 6550, further specifying the focus on medical and surgical instruments, equipment, and supplies. The procurement was conducted as a sole source acquisition, as indicated by the attached Sole Source Justification, reflecting the unique suitability of Phadia reagents for the VA’s diagnostic platforms and requirements. The contracting activity is overseen by Julie Lemire, who serves as the primary point of contact for this agreement. Interested parties or stakeholders may reach her at [email protected] or by phone at 781-226-8882 for further information regarding the award. This BPA is not subject to set-aside requirements, and no special considerations such as small business preferences are noted in the notice. The agreement is intended to provide a stable and compliant supply chain for critical diagnostic reagents, supporting the VA’s long-term operational needs. Contractors evaluating this opportunity should note that the award has already been made and that the procurement is tailored to the specific requirements of the VA’s laboratory operations, with a focus on quality, reliability, and compatibility with existing diagnostic systems. For additional details, including the Sole Source Justification and other relevant attachments, interested parties are directed to the official notice on SAM.gov at https://sam.gov/opp/3ebf66ee0a2245ff8e0e22e4f8a11de2/view.